Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Li Auto Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Li Auto Inc trades at $11.28 (market cap $11.27B). The key difference: Li Auto Inc is far larger — about 3.9× Dyne Therapeutics Inc. Common Stock's market cap, and Li Auto Inc is more actively traded (3,921,121 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Li Auto Inc for 102 Days on average.
| DYN | LI | |
|---|---|---|
Market Cap | $2.86B | $11.27B |
Volume | 3,341,579 | 3,921,121 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $22.72 |
52-Week Low | $14.60 | $10.69 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $2.18B | $673.48M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Li Auto (LI) trades at $11.26, down 1.23% on the day and near its 52-week low, reflecting bearish technical signals and recent delivery declines. The company reported revenue of $112.31B in 2025 with a net income of $1.12B, but profitability metrics like net income margin and ROE remain negative. Recent news highlights challenges in China's EV market, with September 2026 deliveries of 31,817 vehicles showing moderation. Analyst consensus is mixed, with a $15.18 price target suggesting potential upside from current levels.
The outlook for LI is cautious due to intense competition and cash flow pressures, with net cash flow negative $9.0B in 2025. Investment opportunities include new model launches like the Li i9 SUV and global expansion, but risks from market volatility and execution missteps persist. Investors should weigh the company's solid balance sheet against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
